Introduction {#S1}
============

Acne is the most common inflammatory skin condition affecting millions of individuals. Its pathogenesis involves hormonally-induced production of sebum, altered keratinization of the hair follicle, and an inflammatory immune response to the Gram-positive *Propionibacterium acnes* bacterium that resides within the lipid-rich follicle. However, the specific trigger that initiates the development of acne is unknown. Although acne responds to antibiotics, it is not considered to be an infectious disease but may represent an exaggerated immune response to the commensal *P. acnes* bacteria. While not everyone gets acne, nearly all humans are colonized by *P. acnes*, and the density of *P. acnes* does not correlate with the severity of inflammation ([@R10]). Acne patients' immune responses to *P. acnes* may play a larger role in acne than the pathogenicity of *P. acnes* itself ([@R21]).

Systemic retinoids are used to treat severe acne, inflammatory skin diseases, cutaneous T cell lymphoma, neuroblastoma and acute promyelocytic leukemia. Retinoids inhibit inflammatory T~H~17 T cell responses, promote regulatory T cell (Treg) responses, and regulate expression of toll-like receptors (TLRs) ([@R17]; [@R28]). *In vitro* treatment of normal human monocytes with all-*trans* retinoic acid (ATRA) down-regulates TLR-2 expression ([@R12]), but this effect has not been examined in patients treated with systemic retinoids. Isotretinoin (13-*cis* retinoic acid; 13-*cis* RA) is the only drug capable of inducing a long-term or permanent remission of acne; however, the mechanisms leading to this durable response are unknown. Given the role of TLR-2 in initiating immune responses to *P. acnes*, we hypothesized that down-regulation of TLR-2 on monocytes and/or the induction of Treg responses *in vivo* may represent mechanisms by which isotretinoin exerts its long-term effects. In this study, we document the time course of immunomodulation by isotretinoin in treated patients. These findings are relevant not only to treatment of acne, but also to disorders characterized by TLR-2 dysregulation and other retinoid-responsive conditions.

Results {#S2}
=======

Acne patients who were scheduled by their dermatologist to begin treatment with isotretinoin for severe acne were recruited. Normal healthy volunteers without acne or prior history of isotretinoin exposure served as controls. A total of 27 acne patients, 10 males and 17 females, with a mean (± SEM) age of 17.9 ± 1.4 years and 23 normal volunteers, 8 males and 15 females, with a mean (± SEM) age of 22.4 ± 1.5 years were enrolled. Of the 27 acne patients treated with isotretinoin, 10 completed the study through 20 weeks of isotretinoin therapy, eight of whom were reevaluated six months after completing therapy. Of the remaining patients, one discontinued isotretinoin at the direction of his dermatologist, two discontinued due to medication costs, one withdrew consent, and six were lost to follow-up between eight and 20 weeks.

Acne lesion counts were performed at all visits to assess treatment response ([Figure S1](#SD2){ref-type="supplementary-material"}). As an indicator of compliance, serum levels of isotretinoin and its isomers ATRA and 9-*cis* retinoic acid (9-*cis* RA) were assessed ([Figure S2](#SD2){ref-type="supplementary-material"}). Levels were also measured in normal volunteers for comparison. No differences in serum levels of isotretinoin, ATRA, or 9-*cis* RA were found between acne patients at baseline and normal volunteers.

Acne patients' monocytes express significantly greater levels of TLR-2 and significantly lower levels of TLR-4 compared to normal volunteers {#S3}
--------------------------------------------------------------------------------------------------------------------------------------------

Monocytes from acne patients secrete significantly higher levels of cytokines when exposed to *P. acnes* compared to monocytes from normal subjects ([@R21]). We sought to test the hypothesis that monocytes from acne patients express higher levels of TLR-2 when exposed to *P. acnes*, which may account for this observation. At baseline, acne patients' unstimulated monocytes expressed higher levels of TLR-2 than normal volunteers (p = 0.036) ([Figure 1](#F1){ref-type="fig"}). Treatment with *P. acnes* sonicate induced TLR-2 expression in both patients' and volunteers' monocytes, but expression was significantly greater in acne patients' monocytes (p = 0.041). In contrast, *P. acnes*-stimulated monocytes from acne patients at baseline expressed significantly lower levels of TLR-4 compared to normal volunteers (p = 0.016) ([Figure 2](#F2){ref-type="fig"}).

Isotretinoin down-regulates cell surface expression of TLR-2, but not TLR-4, on patients' monocytes in vivo {#S4}
-----------------------------------------------------------------------------------------------------------

To assess the ability of systemic isotretinoin therapy to modulate TLR expression *in vivo*, peripheral blood samples were taken from acne patients prior to and during isotretinoin therapy for acne ([Figure 1](#F1){ref-type="fig"}). Compared to baseline, unstimulated monocytes from patients treated with isotretinoin had significantly decreased TLR-2 expression as early as 1 week of treatment (p \< 0.001), which continued to decrease at each time-point examined (4 weeks, p = 0.004; 8 weeks, p = 0.001; 20 weeks, p = 0.040) ([Figure 1](#F1){ref-type="fig"}). Similarly, decreased TLR-2 expression was noted when monocytes from patients treated with isotretinoin were stimulated with *P. acnes* sonicate (1 week, p = 0.004; 4 weeks, p = 0.017; 8 weeks, p = 0.001; 20 weeks, p = 0.006) ([Figure 1](#F1){ref-type="fig"}) or whole heat-killed *P. acnes* (data not shown). At the 6 month follow-up, the mean fluorescence intensity for TLR-2 expression in stimulated and unstimulated monocytes from the 8 subjects decreased by approximately 70% compared to baseline. In comparison, isotretinoin therapy did not affect TLR-4 expression on acne patients' monocytes at any point during therapy ([Figure 2](#F2){ref-type="fig"}).

Since the majority of patients treated with a full course of isotretinoin (approximately 20 weeks) have a permanent remission of their acne ([@R11]), we sought to test the hypothesis that the dramatic reduction in monocyte TLR-2 expression persists following cessation of isotretinoin therapy. To do this, we modified our clinical protocol and were able to reexamine 8 of the 10 patients that completed 20 weeks of therapy. Six months after stopping isotretinoin, TLR-2 expression in unstimulated and *P. acnes*-stimulated monocytes was still significantly decreased compared to baseline (p = 0.004 and 0.0004, respectively), and not significantly different from normal volunteers ([Figure 1](#F1){ref-type="fig"}). Additionally, TLR-4 expression in monocytes from acne patients six months after treatment was no longer significantly lower than normal volunteers.

Isotretinoin therapy decreases inflammatory cytokine production by patients' monocytes in response to P. acnes {#S5}
--------------------------------------------------------------------------------------------------------------

To determine if isotretinoin altered monocyte cytokine response to *P. acnes* stimulation, supernatants from cultured monocytes were assayed for inflammatory cytokines using bead arrays. Prior to isotretinoin therapy, acne patients' unstimulated monocytes secreted more TNFα than monocytes from normal volunteers, but due to inter-patient variability, did not differ in secretion of other inflammatory cytokines ([Figure 3](#F3){ref-type="fig"}). In response to stimulation with *P. acnes* sonicate, acne patients' monocytes at baseline secreted more IL-1β, IL-6, IL-10, and IL-12p70 than monocytes from normal volunteers. Isotretinoin therapy significantly decreased the secretion of IL-1β, IL-6, IL-10, and IL-12p70 by acne patients' monocytes in response to *P. acnes* compared to pretreatment levels. Cytokine secretion decreased as early as one week of isotretinoin therapy and continued to decrease through 20 weeks of therapy. Additionally, this decrease was sustained at six months after the cessation of therapy. Pearson correlation analysis showed high correlations between TLR-2 expression and secretion of IL-1β (p \< 0.000), IL-6 (p \< 0.000), IL-8 (p = 0.001), and IL-10 (p \< 0.000), but not IL-12p70 (p \> 0.1) in *P. acnes*-stimulated monocytes from volunteers and acne patients during isotretinoin therapy. Similar results were observed in monocytes treated with whole heat-killed *P. acnes* (data not shown).

Isotretinoin therapy does not alter the proportion or function of circulating Treg {#S6}
----------------------------------------------------------------------------------

Treg suppress inflammatory responses and are of great interest as potential therapies for autoimmune and chronic inflammatory diseases. Because the peripheral conversion of undifferentiated T cells into Treg may involve ATRA ([@R17]; [@R25]; [@R28]), as part of the original study we also sought to test the hypothesis that isotretinoin might increase the proportion of circulating Treg in treated patients. Peripheral proportions of CD4+CD25+Foxp3+ Treg were not significantly different in acne patients during isotretinoin therapy compared to baseline ([Figure S3](#SD2){ref-type="supplementary-material"}). Additionally, we found no differences between acne patients and normal volunteers in peripheral proportions of Treg. To investigate whether *in vivo* priming with isotretinoin renders peripheral naïve T cells more likely to differentiate into Treg upon activation, lymphocytes were also stimulated for five days with anti-CD3 and anti-CD28 antibodies, *P. acnes* sonicate, or vehicle. Acne patients' T cells during isotretinoin therapy were not more likely to differentiate into Treg upon stimulation compared to baseline (data not shown). These data suggest that systemic isotretinoin therapy does not necessarily impart Treg-differentiating signals on naïve T cells in the periphery *in vivo*.

To determine if isotretinoin affects peripheral Treg suppressive function, peripheral lymphocyte proliferation was measured using ^3^H-thymidine incorporation assays. Isotretinoin therapy did not affect proliferation of acne patients' lymphocytes at either an unstimulated basal level or in response to activation by anti-CD3/anti-CD28 antibodies or *P. acnes* sonicate ([Figure 4](#F4){ref-type="fig"}). Interestingly, in response to *P. acnes* antigen, acne patients had significantly suppressed lymphocyte proliferation compared to normal volunteers (p= 0.009). Taken together, these data suggest that acne patients have a blunted lymphocyte proliferative response to *P. acnes* and that treatment with isotretinoin does not alter the proportion or function of circulating Treg in acne patients.

Acne patients have higher serum concentrations of IL-10, but not inflammatory cytokines, compared to healthy volunteers {#S7}
-----------------------------------------------------------------------------------------------------------------------

Aside from suppression by Treg, lymphocyte proliferation can also be inhibited by immunosuppressive cytokines such as IL-10. Serum was collected from all subjects during the study for assay of cytokine levels. At baseline, acne patients had significantly higher levels of serum IL-10 compared to normal volunteers (*P* = 0.002) ([Figure 5](#F5){ref-type="fig"}). Interestingly, isotretinoin did not affect serum IL-10 levels at any time-point, and serum IL-10 remained elevated throughout therapy. Of note, these levels are low and their clinical significance is unknown. In contrast, acne patients did not differ from normal volunteers in serum concentrations of IL-1β, IL-6, IL-8, or IL-12p70, nor did isotretinoin therapy significantly affect serum concentrations of these cytokines.

Isotretinoin therapy does not affect cytokine secretion by peripheral blood lymphocytes {#S8}
---------------------------------------------------------------------------------------

Retinoid treatment of T cells can skew helper T cell differentiation and responses. To investigate the effects of systemic isotretinoin therapy on the secretion of T~H~1, T~H~2, and T~H~17-associated cytokines by peripheral lymphocytes, media supernatants from *P. acnes*- and anti-CD3/anti-CD28-stimulated lymphocytes were analyzed at 20 hours and five days of treatment as part of the original study. Isotretinoin did not significantly affect IL-2, IL-4, IL-5, IL-10, IL-17A, TNFα, or IFNγ secretion by lymphocytes in any treatment group (data not shown), suggesting that T cell differentiation was unaffected. Additionally, we did not find any difference in proportions of Treg, Th2, or Th17 cells as assessed by flow cytometry of patients' lymphocytes (data not shown).

Discussion {#S9}
==========

Disorders characterized by inflammation such as acne, rosacea, psoriasis, psoriatic arthritis, and Behcet's disease have been linked to dysregulation of innate immune signaling ([@R2]; [@R4]; [@R29]). Acne, psoriasis, and rosacea are thought to represent disorders of dysbiosis characterized by an imbalance of microorganisms within the cutaneous microbiome that leads to altered innate immune responses and noninfectious skin inflammation (Gallo and Nakatsuji). Additionally, patients with acne, psoriatic arthritis and Behcet's disease have increased expression of TLR-2 on circulating monocytes, implying that the dysregulation of innate immune signaling extends beyond the skin ([@R2]; [@R4]; [@R5]). The increased expression of TLR-2 on acne patients' peripheral monocytes suggests that acne is one such disorder characterized by dysregulation of innate immune signaling in response to *P. acnes*.

Isotretinoin's mechanism of action in inducing long-term remissions of acne is unknown. We sought to test the hypothesis that the systemic administration of isotretinoin, a pro-drug for ATRA would 'normalize' the innate immune response to the *P. acnes* bacteria in patients with severe acne. To our knowledge, this study is the first to demonstrate a durable down-regulation of TLR-2 and down-stream cytokines from systemic administration of a retinoid. Treatment with oral isotretinoin not only decreased TLR-2 expression beginning as early as one week of therapy, but also blunted the rise in TLR-2 expression when monocytes were exposed to *P. acnes*. Most interestingly, the suppression of TLR-2 expression persisted at least six months following completion of therapy, suggesting that this may play a role in the long-term remission of acne following isotretinoin. We did not observe a significant correlation between age and monocyte TLR-2 expression in either acne patients or normal volunteers within the age range of this study, suggesting that the down-regulation of TLR-2 does not represent a physiologic mechanism for the resolution of acne.

The mechanism by which retinoids affect TLR expression is unknown. *In vitro* treatment of normal human monocytes with ATRA down-regulates TLR-2 mRNA ([@R12]), suggesting that isotretinoin operates by a similar mechanism in acne patients' monocytes *in vivo*. Though retinoic acid receptor-binding elements (RAREs) are notably absent from the human TLR-2 gene promoter, it is possible that isotretinoin may be acting through retinoid-X-receptor (RXR) activation via 9-*cis* RA. RXRs dimerize with multiple different nuclear receptors such as the vitamin D receptor (VDR). Activation of VDR can down-regulate TLR-2 expression on normal human monocytes and monocytes from Bechet's patients ([@R4]; [@R19]); however, vitamin D did not affect TLR-2 expression in normal monocytes in our system when incubated with either FBS or human serum (data not shown).

Our study also shows that systemic isotretinoin decreases secretion of inflammatory cytokines by patients' peripheral monocytes to 'normal' levels for at least six months after the cessation of therapy. These results are in accordance with *in vitro* data on the effect of ATRA on monocyte cytokine response to *P. acnes* ([@R12]). Although a minor point of our paper, it is interesting to note that the secretion of IL-10 was higher in acne patients' monocytes at baseline compared to healthy volunteers' in response to *P. acnes*. IL-10 is an anti-inflammatory cytokine that is produced by multiple cell types including Treg, T~H~2 helper T cells, and monocytes. Our findings differ from reports that acne patients' PBMC secrete less IL-10 in response to *P. acnes* than PBMC from healthy volunteers. These differences may be due to the increased severity of acne in our patient population. The inflammatory signature of acne lesions has been examined ([@R9]; [@R22]). Acne lesions express 46-fold higher IL-10 mRNA compared to normal skin ([@R9]), and increased lesional expression of IL-10 has been recently reported in hidradenitis suppuritiva ([@R24]; [@R26]). This increase in IL-10 is thought to represent a compensatory response to intense inflammation ([@R9]). In terms of a putative role of IL-10 in acne, IL-10 induces differentiation of monocytes into CD209+ CD163+ macrophages ([@R15]). CD209+ macrophages have been shown to phagocytose *P. acnes*, and CD163 is a scavenger receptor for heme ([@R13]). In a previous study of gene expression in acne lesions, CD163 was significantly up-regulated in acne lesions compared to normal skin ([@R23]). Interestingly, ATRA has been shown to induce differentiation of CD209+ monocytes *in vitro* ([@R13]). These data would suggest a model wherein IL-10 may in part suppress inflammation in acne lesions by inducing differentiation of monocytes into macrophages that scavenge both *P. acnes* and cellular debris, and retinoic acid may augment this endogenous response. Although isotretinoin decreases IL-10 secretion in monocytes (most likely via TLR-2 down-regulation), it has no effect on the low serum levels of IL-10, possibly representing the contributions of other cell types.

We also present evidence that oral retinoid therapy for up to 20 weeks does not affect peripheral proportions of Treg. Although ATRA concentrations of 10 nM are sufficient for promoting naïve T cell differentiation into Treg *in vitro* ([@R25]), the serum levels of ATRA obtained with therapeutic administration of isotretinoin (in the 200 nM range) had no effect on Treg. This is particularly relevant to the use of retinoids in chemotherapy or chemoprevention where there is a delicate balance between cytotoxicity and preservation of immune surveillance. Indeed, in multiple cancers the numbers or activity of Treg are increased in the periphery and the tumor microenvironment, and higher numbers of Treg correlate with a worse prognosis ([@R3]; [@R14]; [@R16]; [@R20]; [@R27]; [@R30]).

In conclusion, our data suggest that isotretinoin induces remission in acne in part by 'normalizing' acne patients' immune response to *P. acnes* through down-regulation of TLR-2 expression on monocytes. These changes persist for at least six months after the cessation of therapy, suggesting that this effect may represent a long-term action of isotretinoin. Future studies could determine the duration of these effects as well as the effects of isotretinoin on the inflammatory signature of acne microenvironment. TLR-2 down-regulation may not be permanent, but may be maintained long enough to either modulate the adaptive immune response or to merely keep acne in remission until other age-related factors affecting the skin microbiome or sebaceous gland subside.

Methods {#S10}
=======

Human Subjects {#S11}
--------------

Human studies were conducted in accordance with principles of the Declaration of Helsinki as approved by Penn State's Institutional Review Board. All subjects gave written, informed consent. Subjects included males and females ages 12 to 40 who were scheduled to begin treatment with isotretinoin for their moderately severe or severe acne. Patients were not using other acne medications during their isotretinoin therapy. One patient was using topical tretinoin cream at the six month post-isotretinoin visit which has not been shown to alter serum retinoids more than dietary fluctuations ([@R1]). Facial acne was assessed by visual counting of the numbers of inflammatory and noninflammatory lesions at each visit. A 30 mL peripheral blood sample was obtained before starting isotretinoin therapy (baseline) and at 1, 4, 8, and 20 weeks after starting their isotretinoin therapy (0.5 to 1 mg/kg/day) and when possible, six months after the cessation of their isotretinoin therapy. Samples were assessed for retinoid levels and isolation of PBMC. A single 30 mL peripheral blood sample was obtained from healthy volunteers ages 12 to 40 for the same analyses. All blood samples were drawn into sodium-heparin tubes (BD Biosciences).

High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry {#S12}
-------------------------------------------------------------------

Concentrations of the three retinoic acid isomers in patients' serum samples were assayed by HPLC and mass spectrometry. Revisions were made to an established method of sample extraction ([@R18]), and liquid chromatography conditions were modified from the literature ([@R8]). Selective solid-phase extraction was employed varying the wash to 3 mL of 50% methanol and elution to 3 mL of 90% acetonitrile. Run time for the liquid chromatography protocol was reduced from 30 minutes to 20 minutes via gradient, internal standard, and MRM modifications. Analyst software version 1.5.1 (AB Sciex) was used to calibrate curves for the internal standard (acitretin).

P. acnes Cultures {#S13}
-----------------

Reinforced Clostridal Broth (Difco, BD Biosciences) was inoculated with *P. acnes* (ATCC strain 6919), overlaid with N~2~ gas, and grown overnight at 37° C in a shaker until bacteria reached their log growth phase. Bacteria were then washed twice with PBS and resuspended in sterile PBS. Sonicates were made by sonicating suspensions three times for 30 seconds each. The sonicates and the whole heat-killed *P. acnes* were completely non-viable as tested by plating on Brucella agar in described conditions. Weights were measured using wet conditions. All sonicate preparations were stored at -20° C until use.

Stimulation of Monocytes and Lymphocytes {#S14}
----------------------------------------

All sample processing took place in a sterile tissue culture hood under yellow light. Blood samples were processed using a Ficoll-Paque PLUS (GE Healthcare) density gradient according to manufacturer's guidelines. PBMC were separated into lymphocytes and monocytes using the standard adherence method ([@R7]). Samples consistently achieved at least 95% purity with minimal contamination by other cell types as assessed by flow cytometry. Monocytes were treated with vehicle or 1 μg/mL *P. acnes* sonicate in RPMI/10% (v/v) patient serum/antibiotics for 20 hours. Lymphocytes were treated with vehicle, 1 μg/mL *P. acnes* sonicate, or 1 μg/mL anti-CD3 antibody plus 1 μg/mL anti-CD28 antibody for 20 hours or five days. No changes in PBMC viability were observed due to isotretinoin therapy or *in vitro* stimulation.

Flow Cytometry {#S15}
--------------

Anti-human fluorochrome-tagged antibodies were all purchased from BD Biosciences. Single cell suspensions of monocytes and lymphocytes were incubated with the appropriate antibodies in PBS containing 0.1% (w/v) NaN~3~ and 2% (v/v) FBS. For intracellular staining for Foxp3 in lymphocytes, the Foxp3 Staining Buffer Set (eBiosciences) was used according to the manufacturer's directions. All samples were analyzed using an LSR II flow cytometer with FACSDiva Software (both BD Biosciences) and FlowJo Flow Cytometry Analysis Software (Tree Star, Inc.). All samples were normalized to corresponding negative controls.

Cytokine Detection Using Bead Arrays {#S16}
------------------------------------

Supernatants from treated monocytes and lymphocytes and patient serum were assayed for cytokines using Cytometric Bead Array kits (BD Biosciences) according to manufacturer's directions. Samples were run on a LSR II flow cytometer using FACSDiva Software and analyzed using FCAP Analysis Software (both BD Biosciences). The theoretical minimum limit of detection for each cytokine in samples was 0.25 to 0.5 pg/mL.

Lymphocyte Proliferation Assays {#S17}
-------------------------------

Patients' lymphocytes were stimulated with anti-CD3 and anti-CD28 antibodies or *P. acnes* sonicate in RPMI/10% (v/v) patient serum/antibiotics as described above. Cells were plated in triplicate for five days. For the last four hours of incubation, cells were pulsed with 1 μCi/well of tritiated thymidine (Perkin-Elmer). At the end of the incubation, cells were collected and the degree of ^3^H-thymidine incorporation was determined by liquid scintillation analysis.

Statistical Analyses {#S18}
--------------------

For all assays, each patient served as his/her own control, with data from each time-point during isotretinoin treatment being compared back to his/her own baseline value. All patient data was analyzed using paired Student's *t*-tests for comparison of patient data across isotretinoin therapy, and unpaired *t*-tests for comparison between patients and healthy volunteers.
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![Isotretinoin therapy down-regulates surface expression of TLR-2 on patients' monocytes *in vivo*\
Peripheral blood was taken from normal volunteers (Vols; n = 23) and acne patients at baseline and 1, 4, 8, and 20 weeks of isotretinoin therapy and six months after cessation of therapy (n = 25, 19, 19, 17, 10, and 8, respectively). Isolated monocytes were treated with *P. acnes* sonicate or no antigen (unstimulated) and analyzed by flow cytometry. **A)** Dot plots of monocytes from one representative patient are shown. **B)** Displayed is the mean MFI ± SEM of TLR2 expression for patients at baseline versus volunteers (top) as well as patients' TLR-2 levels over the course of isotretinoin therapy (bottom). \**P*\<0.05, \*\**P*\<0.01, and \*\*\**P*\<0.001.](nihms361654f1){#F1}

![Acne patients' monocytes express lower levels of TLR-4 compared to normal volunteers\
Mean MFI ± SEM of TLR-4 is shown for patients at baseline versus volunteers (left) as well as patients' TLR-4 levels over the course of isotretinoin therapy (right). \**P*\<0.05, \*\* *P*\<0.01, and \*\*\**P*\<0.001.](nihms361654f2){#F2}

![Isotretinoin therapy decreases inflammatory cytokine production by acne patients' monocytes in response to *P. acnes*\
Media supernatants from treated monocytes were analyzed for inflammatory cytokine concentrations using bead arrays. Basal cytokine concentrations in the serum (at 10% final concentration) were subtracted from levels found in the media supernatants to calculate the amounts produced *de novo* by the monocytes. Concentrations of cytokines ± SEM are displayed for unstimulated and *P. acnes*-treated monocytes from normal volunteers (Vols) (n = 22) and from patients at baseline (n = 25), 1 week (n = 19), 4 weeks (n = 19), 8 weeks (n = 17), and 20 weeks (n = 10) of isotretinoin therapy as well as six months after the cessation of therapy (n = 8). \**P*\<0.05, \*\**P*\<0.01, and \*\*\**P*\<0.001 compared with patients' baseline. +*P*\<0.05, ++*P*\<0.01, and +++*P*\<0.001 compared with normal volunteers.](nihms361654f3){#F3}

![Lymphocyte proliferative response to *P.acnes* is blunted in acne patients and is unaffected by isotretinoin\
Lymphocytes from normal volunteers (Vols) (n = 11) and from acne patients at baseline (n = 14), 1 week (n = 13), 4 weeks (n = 11), 8 weeks (n = 10), and 20 weeks (n = 5) of isotretinoin therapy were treated with vehicle (no antigen), 1 μM *P. acnes* sonicate, or 1 μg/mL of each anti-CD3 and anti-CD28 antibodies for five days. For the last four hours of incubation, cells were pulsed with 1 μCi of ^3^H-thymidine, and samples were then analyzed by scintillation counting. Mean counts per minute (CPM) ± SEM are shown. +*P*\<0.05 and ++*P*\<0.01 compared with normal volunteers.](nihms361654f4){#F4}

![Acne patients have higher serum levels of IL-10 compared to normal subjects\
Concentrations of cytokines in the serum of normal volunteers (Vols) (n = 13) and acne patients at baseline (n = 26), 1 week (n = 20), 4 weeks (n = 18), 8 weeks (n = 16), and 20 weeks (n = 9) of isotretinoin therapy as well as six months after the cessation of therapy (n = 8) were analyzed using bead arrays. Mean concentrations ± SEM are shown. +*P*\<0.05 and ++*P*\<0.01 compared with normal volunteers.](nihms361654f5){#F5}
